Polymorphs and solvates of a cocrystal involving an analgesic drug, ethenzamide, and 3,5-dinitrobenzoic acid

Crystal Growth and Design

Volumn 10, Issue 5, 2010, Pages 2229-2238

  Aitipamula, Srinivasulu ^a   Chow, Pui Shan ^a   Tan, Reginald B H ^a,b  

^a INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952014654     PISSN: 15287483     EISSN: 15287505     Source Type: Journal    
DOI: 10.1021/cg9015178     Document Type: Article

References (66)

1. Vishweshwar, P.; McMahon, J. A.; Zaworotko, M. J. In Frontiers in Crystal Engineering Tiekink, E. R. T., Vittal, J. J., Eds.; Wiley: Chichester, U.K., 2006; pp 25-49.
2. Remenar, J. F.; Morissette, S. L.; Peterson, M. L.; Moulton, B.; MacPhee, J. M.; Guzman, H. R.; Almarsson, Ö. J. Am. Chem. Soc. 2003, 125, 8456
3. McNamara, D. P.; Childs, S. L.; Giordano, J.; Iarriccio, A.; Cassidy, J.; Shet, M. S.; Mannion, R.; O'Donnell, E.; Park, A. Pharm. Res. 2006, 23, 1888
4. Hickey, M. B.; Peterson, M. L.; Scoppettuolo, L. A.; Morrisette, S. L.; Vetter, A.; Guzmán, H.; Remenar, J. F.; Zhang, Z.; Tawa, M. D.; Haley, S.; Zaworotko, M. J.; Almarsson, Ö. Eur. J. Pharm. Biopharm. 2007, 67, 112
5. Updated list of GRAS chemicals may be downloaded from http://www.cfsan.fda.gov/dms/eafus.html.
6. Almarsson, Ö.; Zaworotko, M. J. Chem. Commun. 2004, 1889
7. Trask, A. V. Mol. Pharm. 2007, 4, 301
8. Schultheiss, N.; Newman, A. Cryst. Growth Des. 2009, 9, 2950
9. Stahly, G. P. Cryst. Growth Des. 2009, 9, 4212
10. Good, D. J.; Rodríguez-Hornedo, N. Cryst. Growth Des. 2009, 9, 2252
11. Bak, A.; Gore, A.; Yanez, E.; Stanton, M.; Tufekcic, S.; Syed, R.; Akrami, A.; Rose, M.; Surapaneni, S.; Bostick, T.; King, A.; Neervannan, S.; Ostovic, D.; Koparkar, A. J. Pharm. Sci. 2008, 97, 3942
12. Trask, A. V.; Sam Motherwell, W. D.; Jones, W. Int. J. Pharm. 2006, 320, 114
13. Basavoju, S.; Boström, D.; Velaga, S. P. Cryst. Growth Des. 2006, 6, 2699
14. Trask, A. V.; Motherwell, W. D. S.; Jones, W. Cryst. Growth Des. 2005, 5, 1013
15. Bernstein, J. Polymorphism in Molecular Crystals; Clarendon: Oxford, U.K., 2002.
16. MacNicol, D. D.; Toda, F.; Bishop, R. Solid-State Supramolecular Chemistry, Crystal Engineering; Comprehensive Supramolecular Chemistry; Pergamon Press: Oxford, U.K., 1996; Vol. 6.
17. Nassimbeni, L. R. Acc. Chem. Res. 2003, 36, 631
18. Nangia, A. In Nanoporous Materials: Science and Engineering; Lu, G. Q.; Zhao, X. S., Eds.; Imperial College Press: London, 2004; pp 165-187.
19. Byrn, S. R.; Pfeiffer, R. R.; Stowell, J. G. Solid-State Chemistry of Drugs, 2 nd ed.; SSCI Inc.: West Lafayette, IN, 1999.
20. Aitipamula, S.; Chow, P. S.; Tan, R. B. H. CrystEngComm 2009, 11, 889
21. Aitipamula, S.; Chow, P. S.; Tan, R. B. H. CrystEngComm 2009, 11, 1823
22. Braga, D.; Palladino, G.; Polito, M.; Rubini, K.; Grepioni, R.; Chierotti, M. R.; Gobetto, R. Chem.-Eur. J. 2008, 14, 10149
23. Sokolov, A. N.; Swenson, D. C.; MacGillivray, L. R. Proc. Natl. Acad. Sci. 2008, 105, 1794
24. Babu, N. J.; Reddy, L. S.; Aitipamula, S.; Nangia, A. Chem. Asian J. 2008, 3, 1122
25. Porter, W. W., III; Elie, S. C.; Matzger, A. J. Cryst. Growth Des. 2008, 8, 14
26. Sreekanth, B. R.; Vishweshwar, P.; Vyas, P. Chem. Commun. 2007, 2375 and references therein
27. ter Horst, J. H.; Cains, P. W. Cryst. Growth Des. 2008, 8, 2537
28. Vishweshwar, P.; McMahon, J. A.; Peterson, M. L.; Hickey, M. B.; Shattock, T. R.; Zaworotko, M. J. Chem. Commun. 2005, 4601
29. Friš̌cÌŒić, T.; Trask, A. V.; Motherwell, W. D. S.; Jones, W. Cryst. Growth Des. 2008, 8, 1605
30. Banerjee, R.; Bhatt, P. M.; Desiraju, G. R. Cryst. Growth Des. 2006, 6, 1468
31. Bhogala, B. R.; Basavoju, S.; Nangia, A. Cryst. Growth Des. 2005, 5, 1683
32. Thallapally, P. K.; Dobrzaśska, L.; Gingrich, T. R.; Wirsig, T. B.; Barbour, L. J.; Atwood, J. L. Angew. Chem., Int. Ed. 2006, 45, 6506
33. Atwood, J. L.; Barbour, L. J.; Jerga, A.; Schottel, B. L. Science 2002, 298, 1000
34. Karki, S.; FrisÌŒcÌŒić, T.; Jones, W.; Motherwell, W. D. S. Mol. Pharm. 2007, 4, 347
35. Uehara, H.; Otsuka, K.; Izumi Cancer Letters 1998, 135, 83
36. Aoki, S.; Mizutani, T.; Danjo, D. Chem. Pharm. Bull. 2000, 48, 140
37. Kawano, O.; Sawabe, T.; Misaki, N.; Fukawa, K. Jpn. J. Pharmacol. 1978, 28, 829
38. Moribe, K.; Tsuchiya, M.; Tozuka, Y.; Yamaguchi, K.; Oguchi, T.; Yamamoto, K. Chem. Pharm. Bull. 2004, 52, 524
39. Pagola, S.; Stephens, P. W. Acta Crystallogr., Sect. C 2009, 65, o583
40. Cambridge Structural Database (version 5.29) ConQuest 1.10, May 2009 update; Cambridge Crystallographic Data Centre, Cambridge. U.K., 2007; to be found under www.ccdc.cam.ac.uk.
41. Sheldrick, G. M. SHELXS-97 and SHELXL-97, Programs for the Solution and Refinement of Crystal Structures; University of Göttingen, Göttingen, Germany, 1997.
42. It should be mentioned here that the CSD does not contain information pertaining to pharmaceutical relevance of many cocrystal components, and it is often difficult to judge whether a particular compound is pharmaceutically relevant or not just based on its compound name. Hence, our estimation of pharmaceutical cocrystals is based on a general search of all these compounds, and it is possible that the actual number of pharmaceutical cocrystals could be more than 137 of the total 3624 cocrystals.
43. Spek, A. L. Acta Crystallogr., Sect. D 2009, 65, 148
44. Computed in Materials Studio using Forcite module, COMPAS force field. www.accelrys.com.
45. Ostwald, W. Z. Phys. Chem. 1897, 22, 289
46. Jetti, R. K. R.; Boese, R.; Sarma, J. A. R. P.; Reddy, L. S.; Vishweshwar, P.; Desiraju, G. R. Angew. Chem., Int. Ed. 2003, 42, 1963
47. Nangia, A.; Desiraju, G. R. Top. Curr. Chem. 1998, 198, 57
48. Vishweshwar, P.; Nangia, A.; Lynch, V. M. Cryst. Growth Des. 2003, 3, 783
49. McMahon, J. A.; Bis, J. A.; Vishweshwar, P.; Shattock, T. R.; McLaughlin, O. L.; Zaworotko, M. J. Z. Kristallogr. 2005, 220, 340
50. Caira, M. R.; Nassimbeni, L. R. Comprehensive Supramolecular Chemistry; Atwood, J. L.; Davies, J. E. D.; MacNicol, D.; Vögtle, F., Eds.; Elsevier Science: Oxford, U.K., 1996; Vol. 6, pp 825-850.
51. Etter, M. C.; Frankenbach, G. M.; Adsmond, D. A. Mol. Cryst. Liq. Cryst. 1990, 187, 285
52. Sokolov, A. N.; Friščič, T.; MacGillivray, L. R. J. Am. Chem. Soc. 2006, 128, 2806
53. MacGillivray, L. R.; Papaefstathiou, G. S.; FrisÌŒcÌ Œić, T.; Hamilton, T. D.; BucÌŒar, D.-K.; Chu, Q.; Varshney, D. B.; Georgiev, I. G. Acc. Chem. Res. 2008, 41, 280
54. McCrone, W. C. In Polymorphism in Physics and Chemistry of the Organic Solid State; Fox, D.; Labes, M. M.; Weissberger, A., Eds.; Wiley Interscience: New York, 1965; Vol. 2, pp 725-767.
55. van de Streek, J. CrystEngComm 2007, 9, 350
56. Desiraju, G. R. J. Chem. Soc., Chem. Commun. 1991, 426
57. Brychczynska, M.; Davey, R. J.; Pidcock, E. New J. Chem. 2008, 32, 1754
58. Nangia, A.; Desiraju, G. R. Chem. Commun. 1999, 605
59. Görbitz, C. H.; Hersleth, H.-P. Acta Crystallogr., Sect. B 2000, 56, 526
60. van de Streek, J.; Motherwell, S. CrystEngComm 2007, 9, 55
61. Gillon, A. L.; Feeder, N.; Davey, R. J.; Storey, R. Cryst. Growth Des. 2003, 3, 663
62. Infantes, L.; Motherwell, S. CrystEngComm 2002, 4, 454
63. Infantes, L.; Chisholm, J.; Motherwell, S. CrystEngComm 2003, 5, 480
64. Infantes, L.; Fábián, L.; Motherwell, W. D. S. CrystEngComm 2007, 9, 65
65. As part of an analysis of the occurrence of pharmaceutically acceptable anions and cations in the CSD, Haynes et al. retrieved the hydrates of cocrystals that contain at least one pharmaceutically acceptable acid or base. It was found that, of the 381 total cocrystals, 59 (15.5%) were hydrates. See Haynes, D. A.; Jones, W.; Motherwell, W. D. S. J. Pharm. Sci. 2005, 94, 2111
66. 2+, COOÂ etc., significantly increases the chances of forming hydrates (see refs 63 and 65).